InMed and the laboratory of Dr. Vikramaditya Yadav at the University of British Columbia collaborate on a proprietary biosynthesis technology to produce bioidentical, high purity, high grade cannabinoids. The host selected is E.coli. In this video, Dr. Yadav talks how an E.coli-based system is uniquely suited for producing cannabinoids.
The Dales Report: InMed Pharmaceuticals: Commercializing The Development Of Rare Cannabinoids For The Wellness Market
Shadd Dales of The Dales Report interviews InMed CEO, Eric A. Adams, about the rare cannabinoid market and being able to manufacture rare cannabinoids, like
May 17, 2022
